Patents by Inventor Rudi Brands
Rudi Brands has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11103562Abstract: Present invention relates to a composition for use in the treatment of arthritides. Alkaline phosphatase (AP), an ectophosphatase with an anti-inflammatory and barrier protecting mechanism of action shows potent anti-rheumatoid arthritis (anti-RA) efficacy in a rat model for arthritis. In this model RA was induced by subcutaneous immunization with a mixture of methylated bovine serum albumin (mBSA), CFA (complete Freund's adjuvant antigen) and CBP (custom Bordetella pertussis antigen) and intra-articular injections of mBSA. Results were comparable with those obtained for MTX, the drug reference compound for the treatment of RA. Both knee swelling over time and the number of invading macrophages were found to be reduced with AP treatment, either applied in prophylactic treatment or therapeutic treatment, and comparable to the MTX effects. AP was found effective both as prophylactic, and as therapeutic intervention.Type: GrantFiled: December 12, 2017Date of Patent: August 31, 2021Assignee: AMRIF BVInventors: Rudi Brands, Willem Seinen, Carolina Frederika Maria Molthoff, Gerrit Jansen, Ronald Sake Oosting
-
Publication number: 20200121765Abstract: Present invention relates to a composition for use in the treatment of arthritides. Alkaline phosphatase (AP), an ectophosphatase with an anti-inflammatory and barrier protecting mechanism of action shows potent anti-rheumatoid arthritis (anti-RA) efficacy in a rat model for arthritis. In this model RA was induced by subcutaneous immunization with a mixture of methylated bovine serum albumin (mBSA), CFA (complete Freund's adjuvant antigen) and CBP (custom Bordetella pertussis antigen) and intra-articular injections of mBSA. Results were comparable with those obtained for MTX, the drug reference compound for the treatment of RA. Both knee swelling over time and the number of invading macrophages were found to be reduced with AP treatment, either applied in prophylactic treatment or therapeutic treatment, and comparable to the MTX effects. AP was found effective both as prophylactic, and as therapeutic intervention.Type: ApplicationFiled: December 12, 2017Publication date: April 23, 2020Inventors: Rudi Brands, Willem Seinen, Carolina Frederika Maria Molthoff, Gerrit Jansen, Ronald Sake Oosting
-
Publication number: 20170072027Abstract: The present invention relates to the treatment of neurodegenerative diseases, i.e. a group of chronic, progressive disorders characterized by the gradual loss of neurons in discrete areas of the central nervous system (CNS). Specifically, the present invention relates to alkaline phosphatase for use in the treatment of neurodegenerative disorders, preferably neurodegenerative disorders selected from the group consisting of Alzheimer's Disease; Parkinson's Disease; Amylotrophic Lateral Sclerosis; Multiple Sclerosis and Stroke.Type: ApplicationFiled: April 30, 2015Publication date: March 16, 2017Inventors: Rudi Brands, Willem Seinen
-
Method for increasing the activity of the immune system of a mammal at risk of inflammatory diseases
Patent number: 8784805Abstract: The present invention relates to methods for increasing the activity of the immune system and, especially, to methods for increasing the activity of the immune system by modulation of endogenous ectophosphatase levels. According to a particularly preferred embodiment the present invention relates to methods for the prophylaxis of mammals, and especially human mammals, at risk of inflammatory diseases such as mammals suffering from conditions such as surgery, digestive tract diseases, respiratory diseases, skin diseases, burn wounds, smoke inhalation, intoxication, severe blood loss, food poisoning, chemotherapy, radiation therapy, severe trauma or liver diseases, immunocompromised conditions. For this, the present invention provides use of an ectophosphatase for the preparation of a medicament for the prophylaxis of a mammal at risk of inflammatory diseases.Type: GrantFiled: February 27, 2009Date of Patent: July 22, 2014Assignee: Alloksys Life Sciences B.V.Inventor: Rudi Brands -
Patent number: 8735087Abstract: The present invention provides a use for alkaline phosphatase for the manufacture of a medicament for the prevention or reduction of toxic LPS influx through a mucosal lining of a mammalian body cavity. A source of alkaline phosphatase is administered for the prophylaxis or treatment of LPS mediated or exacerbated diseases. The invention also provides compositions comprising a source of alkaline phosphatase for the prevention or reduction of (toxic) LPS influx or passage through mucosal layers.Type: GrantFiled: February 15, 2013Date of Patent: May 27, 2014Assignee: PharmAAware Sepsis B.V.Inventors: Rudi Brands, Klaas Poelstra
-
Patent number: 8574863Abstract: The present invention provides a use for alkaline phosphatase for the manufacture of a medicament for the prevention or reduction of toxic LPS influx through a mucosal lining of a mammalian body cavity. A source of alkaline phosphatase is administered for the prophylaxis or treatment of LPS mediated or exacerbated diseases. The invention also provides compositions comprising a source of alkaline phosphatase for the prevention or reduction of (toxic) LPS influx or passage through mucosal layers.Type: GrantFiled: February 4, 2005Date of Patent: November 5, 2013Assignee: PharmAAware Sepsis B.V.Inventors: Rudi Brands, Klaas Poelstra
-
Publication number: 20110142817Abstract: Compositions comprising a source of alkaline phosphatase that prevent or reduce toxic influx of lipopolysaccharide (LPS) through mucosal layers of a mamalian body cavity and methods of using these compositions for those purposes are disclosed. Such a source of alkaline phosphatase, preferably in a medical food such as infant milk formula, is eaten, drunk or otherwise administered for prophylaxis or treatment of LPS-mediated or LPS-exacerbated disease.Type: ApplicationFiled: July 6, 2010Publication date: June 16, 2011Applicant: PHARMAAWARE SEPSIS B.V.Inventors: Rudi BRANDS, Klaas Poelstra
-
Method for Increasing the Activity of the Immune System of a Mammal at Risk of Inflammatory Diseases
Publication number: 20110052560Abstract: The present invention relates to methods for increasing the activity of the immune system and, especially, to methods for increasing the activity of the immune system by modulation of endogenous ectophosphatase levels. According to a particularly preferred embodiment the present invention relates to methods for the prophylaxis of mammals, and especially human mammals, at risk of inflammatory diseases such as mammals suffering from conditions such as surgery, digestive tract diseases, respiratory diseases, skin diseases, burn wounds, smoke inhalation, intoxication, severe blood loss, food poisoning, chemotherapy, radiation therapy, severe trauma or liver diseases, immunocompromised conditions. For this, the present invention provides use of an ectophosphatase for the preparation of a medicament for the prophylaxis of a mammal at risk of inflammatory diseases.Type: ApplicationFiled: February 27, 2009Publication date: March 3, 2011Applicant: ALLOKSYS LIFE SCIENCES B.V.Inventor: Rudi Brands -
Publication number: 20090010912Abstract: The present invention provides a use for alkaline phosphatase for the manufacture of a medicament for the prevention or reduction of toxic LPS influx through a mucosal lining of a mammalian body cavity. A source of alkaline phosphatase is administered for the prophylaxis or treatment of LPS mediated or exacerbated diseases. The invention also provides compositions comprising a source of alkaline phosphatase for the prevention or reduction of (toxic) LPS influx or passage through mucosal layers.Type: ApplicationFiled: February 4, 2005Publication date: January 8, 2009Applicant: PHARMAAWARE SEPSIS B.V.Inventors: Rudi Brands, Klaas Poelstra
-
Publication number: 20070148753Abstract: The present invention relates to a method for the preparation of cells for use in the production of biologicals, by culturing cells up till a desired cell volume of a preproduction batch, where after in a repeated discontinous process: a) part of the cells of the preproduction batch is used for the preparation of at least one production batch, and b) the remaining part of the cells of the preproduction batch is used as a seed for the preparation of at least one subsequent preproduction batch.Type: ApplicationFiled: January 18, 2007Publication date: June 28, 2007Inventor: Rudi Brands
-
Patent number: 6793928Abstract: The present invention relates to a vaccine containing at least one particulate immunogen and an adjuvanting amount of B subunits of heat-labile enterotoxin characteristic of E. Coli. More in particular, this invention relates to vaccines wherein the adjuvanting LTB is free from contaminating A subunits or holotoxin. To this end, preferably, use is made of LTB prepared by recombinant DNA techniques. The particulate immunogens can relate to or can be derived from e.g. viruses, bacteria or fungi. This vaccine is particularly suitable for the induction of a protective response against said particulate immunogen upon mucosal (e.g. intra-nasal) administration. It was found that such administration results in both systemic and mucosal protection against the pathogen to which the particulate immunogen relates.Type: GrantFiled: December 13, 2000Date of Patent: September 21, 2004Assignees: Duphar International Research BV, Universiteit Van GroningenInventors: Gustaaf J. M. van Scharrenburg, Rudi Brands, Lolke de Haan, Willem Ronald Verweij, Jan C. Wilschut, Etienne Agsteribbe
-
Patent number: 5948410Abstract: The present invention is concerned with an Influenza surface antigen vaccine obtainable by production from Influenza Viruses propagated on animal cell culture and having a host cell DNA content equal to or less than 25 pg per dose. The present invention is also concerned with a method for the preparation of surface antigen proteins from Influenza Viruses propagated on an animal cell culture comprising the subsequent steps of:a. treatment of the whole virus containing fluid obtained from the cell culture with a DNA digesting enzyme, andb. adding a cationic detergent,followed by isolation of the surface antigen proteins.Type: GrantFiled: April 6, 1998Date of Patent: September 7, 1999Assignee: Duphar International Research B.V.Inventors: Gustaar J. M. Van Scharrenburg, Rudi Brands